Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in ...

The US Radiotherapy Market is projected to reach US$2.49 billion by 2030 from US$3.25 billion in 2024, at a CAGR of 4.6%. The US radiotherapy ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.

The quest for more effective cancer radiotherapy continues apace, with Telix Pharmaceuticals (ASX:TLX) today reporting “encouraging” preliminary results from its phase II study to treat recurrent high ...

Prostate cancer is the most common cancer in men worldwide. Thanks to scientific breakthroughs, there are more ways than ever to treat it — especially when it’s caught early. One ...

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...